<\/p>\n
Eli Lilly and Co_ by Sergio Photone via Shutterstock <\/p>\n
Indianapolis, Indiana-based Eli Lilly and Company (LLY<\/a>) discovers and develops various drugs and medicines. It operates as one of the largest pharmaceutical companies in the world and boasts a diverse portfolio of numerous successful drugs, including Mounjaro, Trulicity, Verzenio, and more. With a market cap of\u00a0$816.7 billion<\/a>, its operations span various countries in the Americas, EMEA, and the Indo-Pacific.<\/p>\n Despite its notable strengths, the pharma giant has lagged behind the broader market over the past year. LLY stock prices have\u00a0gained 16.1%<\/a> on a YTD basis and 9.5% over the past 52 weeks, compared to the S&P 500 Index\u2019s ($SPX<\/a>)\u00a016.5% gains<\/a> in 2025 and 19.6% returns over the past year.<\/p>\n Narrowing the focus, LLY outperformed the Health Care Select Sector SPDR Fund\u2019s (XLV<\/a>)\u00a05% uptick<\/a> in 2025 and 2.2% decline over the past year.<\/p>\n www.barchart.com<\/a><\/p>\n Eli Lilly\u2019s stock prices\u00a0gained 3.8%<\/a> in the trading session following the release of its\u00a0impressive Q3 results<\/a> on Oct. 30. Driven by the solid volume growth in Mounjaro and Zepbound sales, the company\u2019s topline for the quarter skyrocketed 53.9% year-over-year to $17.6 billion, beating the Street\u2019s expectations by a massive 9.9%. Meanwhile, its adjusted EPS surged by a humongous 494.9% year-over-year to $7.02, surpassing the consensus estimates by 16.6%. Further, observing the trend, Eli Lilly raised its full-year revenues and EPS guidance, boosting investor confidence.<\/p>\n For the full fiscal 2025, ending in December, analysts expect LLY to deliver an adjusted EPS of $24.04, up 85.1% year-over-year. The company has a mixed earnings surprise history. While it missed the Street\u2019s bottom-line estimates once over the past four quarters, it surpassed the projections on three other occasions.<\/p>\n Among the 27 analysts covering the LLY stock, the consensus rating is a \u201cStrong Buy<\/a>.\u201d That\u2019s based on 19 \u201cStrong Buys,\u201d two \u201cModerate Buys,\u201d and six \u201cHolds.\u201d<\/p>\n www.barchart.com<\/a><\/p>\n This configuration is slightly less optimistic than three months ago, when 20 analysts gave \u201cStrong Buy\u201d recommendations.<\/p>\n On Oct. 31, Cantor Fitzgerald analyst Carter Gould maintained an \u201cOverweight<\/a>\u201d rating on LLY and raised the price target from $925 to $985.<\/p>\n LLY\u2019s mean price target of $925.50 represents a modest premium of 3.2% from current price levels. Meanwhile, the street-high target of $1,190 suggests a notable potential upside of 32.7%.<\/p>\n On the date of publication, Aditya Sarawgi<\/a> did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly and Co_ by Sergio Photone via Shutterstock Indianapolis, Indiana-based Eli Lilly and Company (LLY) discovers and…\n","protected":false},"author":2,"featured_media":262403,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500,40949],"class_list":{"0":"post-262402","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-au","9":"tag-australia","10":"tag-health","11":"tag-healthcare","12":"tag-n-a"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/262402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=262402"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/262402\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/262403"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=262402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=262402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=262402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![](\"https:\/\/barchart-news-media-prod.aws.barchart.com\/SANDP\/a11fd790f9b7dd7aa4c693e6605a313c\/9wwgzdvajy5pnho6.png\")
<\/p>\n![](\"https:\/\/barchart-news-media-prod.aws.barchart.com\/SANDP\/a11fd790f9b7dd7aa4c693e6605a313c\/mjmylnhyy9x8sgo9.png\")
<\/p>\n